The Food and Drug Administration (FDA) will survey 250 compounding pharmacies that produce customized versions of prescription drugs, amid ongoing concerns about safety and quality. Compounded drugs, which are not FDA-approved, have surged in popularity, especially copycat GLP-1 drugs for weight loss, due to shortages of brand-name medications like Wegovy and Ozempic. The FDA plans to halt production of compounded GLP-1s by May 22, now that the shortages have ended. The survey, initiated under the Biden administration and continued by Health and Human Services Secretary Robert F. Kennedy Jr., will assess business practices, quality control, and regulatory interactions to inform future oversight. (Article here)